Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis

Annals of Neurology

Volumn 73, Issue 3, 2013, Pages 408-418

  Benjamin Larman, H ^a,b,c,d,e   Salajegheh, Mohammad ^f,g   Nazareno, Remedios ^f   Lam, Theresa ^g   Sauld, John ^g   Steen, Hanno ^g   Won Kong, Sek ^g   Pinkus, Jack L ^f,g   Amato, Anthony A ^f   Elledge, Stephen J ^a,b,c   Greenberg, Steven A ^f,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; 5' NUCLEOTIDASE 1A; AUTOANTIBODY; AUTOANTIGEN; DNA; EPITOPE; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NT5C1A PROTEIN, HUMAN; PROTEIN TDP-43; TAR DNA BINDING PROTEIN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BLOOD EXAMINATION; BLOOD SAMPLING; CELL VACUOLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXOME; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MUSCLE ATROPHY; MUSCLE BIOPSY; PEPTIDE LIBRARY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; BLOOD; DERMATOMYOSITIS; DNA SEQUENCE; EPITOPE MAPPING; FEMALE; GENETICS; GENOME; IMMUNOLOGY; IMMUNOPRECIPITATION; MALE; METABOLISM; MIDDLE AGED; MYELITIS; PATHOLOGY; POLYMYOSITIS; SKELETAL MUSCLE;

5'-NUCLEOTIDASE; AGED; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; CYTOSOL; DERMATOMYOSITIS; DNA-BINDING PROTEINS; EPITOPE MAPPING; FEMALE; GENOME; HUMANS; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; MIDDLE AGED; MUSCLE, SKELETAL; MYELITIS, TRANSVERSE; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; SEQUENCE ANALYSIS, DNA; VACUOLES;

MLCS; MLOWN;

EID: 84876499456     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23840     Document Type: Article

References (39)

1. Needham M, Mastaglia FL,. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620-631.
2. Greenberg SA,. Inclusion body myositis. Curr Opin Rheumatol 2011; 23: 574-578.
3. Greenberg SA,. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010; 12: 221-228.
4. Arahata K, Engel AG,. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193-208.
5. Engel AG, Arahata K,. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-215.
6. Arahata K, Engel AG,. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988; 23: 168-173.
7. Arahata K, Engel AG,. Monoclonal antibody analysis of mononuclear cells in myopathies. V: Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988; 23: 493-499.
8. Greenberg SA,. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69: 2008-2019.
9. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59: 1170-1182.
10. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65: 1782-1787.
11. Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007; 178: 547-556.
12. Salajegheh M, Pinkus JL, Amato AA, et al. Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 2010; 42: 576-583.
13. Salajegheh M, Lam T, Greenberg SA,. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011; 6: e20266.
14. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55: 1385-1387.
15. Hengstman GJ, van Engelen BG, ter Laak HJ, Gabreels-Festen AA,. Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy. J Neurol 2000; 247: 882-884.
16. Mastaglia F, Price P, Walters S, et al. Familial inclusion body myositis in a mother and son with different ancestral MHC haplotypes. Neuromuscul Disord 2006; 16: 754-758.
17. Chahin N, Engel AG,. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-424.
18. Parker KC, Walsh RJ, Salajegheh M, et al. Characterization of human skeletal muscle biopsy samples using shotgun proteomics. J Proteome Res 2009; 8: 3265-3277.
19. Greenberg SA, Salajegheh M, Judge DP, et al. Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Ann Neurol 2012; 71: 141-145.
20. Larman HB, Zhao Z, Laserson U, et al. Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 2011; 29: 535-541.
21. Drmanac R, Sparks AB, Callow MJ, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010; 327: 78-81.
22. Hunsucker SA, Spychala J, Mitchell BS,. Human cytosolic 5′-nucleotidase I: characterization and role in nucleoside analog resistance. J Biol Chem 2001; 276: 10498-10504.
23. Vanderlugt CL, Miller SD,. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
24. Roy A, Kucukural A, Zhang Y,. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 2010; 5: 725-738.
25. Pruijn G, Pluk H, Van Hoeve B, et al. Autoantibodies to cytosolic 5′nucleotidase IA in inclusion body myositis. Ann Neurol (in press).
26. Hunsucker SA, Mitchell BS, Spychala J,. The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005; 107: 1-30.
27. Kota S, Kumar CV, Misra HS,. Characterization of an ATP-regulated DNA-processing enzyme and thermotolerant phosphoesterase in the radioresistant bacterium Deinococcus radiodurans. Biochem J 2010; 431: 149-157.
28. Greenberg SA, Pinkus JL, Amato AA,. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34: 406-416.
29. Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008; 18: 27-33.
30. Nishii M, Nakano S, Nakamura S, et al. Myonuclear breakdown in sporadic inclusion body myositis is accompanied by DNA double strand breaks. Neuromuscul Disord 2011; 21: 345-352.
31. Nalbantoglu J, Karpati G, Carpenter S,. Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144: 874-882.
32. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79: 1186-1189.
33. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40: 19-31.
34. Hengstman GJ, van Engelen BG, van Venrooij WJ,. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16: 692-699.
35. Targoff IN,. Autoantibodies and their significance in myositis. Curr Rheumatol Rep 2008; 10: 333-340.
36. Mammen AL,. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-153.
37. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134 (pt 11): 3176-3184.
38. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79: 1056-1060.
39. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40: 581-586.